Liver Cancer
Advertisement
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Trial results show no significant benefit of adding chemoradiation to adjuvant chemotherapy in resected gallbladder cancer.
SBRT shows promise for liver tumor control, but hepatobiliary toxicity remains a concern.
Atezolizumab plus bevacizumab shows promising efficacy and tolerability for advanced HCC with Child-Pugh B cirrhosis.
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
SBRT with sorafenib is shown to be associated with a clinically important but not statistically significant improved OS rate.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.